GlassScriptPhysician profile
Hope Chiodi
NPI 1457805749
$1,301.11
in general payments reported to CMS, 2019-2025
28 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.34 · 2022: $94.26 · 2023: $454 · 2024: $338 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,098 · Education: $82.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.52 |
| Education | $82.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $160.73 | 2023-2025 | |
| Abbvie INC. | $137.13 | 2023-2025 | |
| Tempus Ai, INC | $96.48 | 2025 | Xt Cdx |
| Astrazeneca Pharmaceuticals LP | $81.31 | 2023 | Calquence, Lynparza |
| Exelixis INC. | $75.06 | 2022-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $73.75 | 2023-2024 | Welireg, Keytruda, Lynparza |
| Incyte Corporation | $73.08 | 2022-2025 | Jakafi, Monjuvi |
| Ipsen Biopharmaceuticals, INC | $72.78 | 2023-2025 | Onivyde |
| Lilly USA, LLC | $48.40 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Emd Serono, INC. | $43.28 | 2024-2025 | |
| Pfizer INC. | $41.74 | 2022-2024 | |
| Adc Therapeutics America, INC. | $39.01 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $38.10 | 2025 | Lynozyfic |
| Astellas Pharma US INC | $30.61 | 2024 | Vyloy |
| Daiichi Sankyo INC. | $28.91 | 2025 | Enhertu |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $27.48 | 2025 | Beleodaq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.34 | 2021 | |
| Array Biopharma INC | $24.89 | 2025 | Tukysa, Braftovi, Mektovi |
| Morphosys, US INC. | $22.45 | 2023 | Monjuvi |
| Seagen INC. | $21.98 | 2023 | Padcev |
| Eisai INC. | $21.13 | 2024 | |
| Sumitomo Pharma America, INC. | $20.00 | 2023 | Orgovyx |
| Agios Pharmaceuticals, INC. | $18.94 | 2024 | Pyrukynd |
| Amgen INC. | $18.24 | 2023 | Nplate, Vectibix, Xgeva |
| Genmab U.S., INC. | $17.00 | 2023 | Tivdak |
| Janssen Pharmaceuticals, INC | $15.48 | 2022 | |
| Cti Biopharma Corp. | $14.72 | 2023 | Vonjo |
| Alexion Pharmaceuticals, INC. | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Chiodi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.